fatty acid oxidation raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-14. Anything still debated is marked as such rather than presented as settled.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
Safety concerns emerged from long-term animal studies. In rodents given the compound for extended periods, researchers found an increased incidence of certain cancers, including liver and bladder tumors. These findings contributed to the discontinuation of clinical development. Whether similar risks apply to short-term or low-level exposure in humans is not established, and controlled human safety data are limited. The relevance of high-dose rodent carcinogenicity findings to human use remains a subject of debate.
Human trials of GW501516 were small and short in duration. They examined lipid levels, glucose handling, and other metabolic markers, but the programs were halted after the animal cancer findings. No approved therapeutic product exists, and published human data are insufficient for establishing long-term safety. Reports of use for athletic performance come mainly from non-clinical settings and cannot be verified through controlled trials. Independent testing of products sold as cardarine has found inconsistent purity and labeling.
Laboratory studies indicate that GW501516 activates PPARδ, a nuclear receptor involved in fatty acid oxidation and energy metabolism. In rodent experiments, treated animals often showed increased endurance and reduced fat mass. These effects were observed under controlled conditions and do not establish safe or effective use in humans. The exact dose-response relationship in humans remains poorly characterized. Species differences in metabolism can affect how results translate across animals and people.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white solid | Typical form of reference material |
| Solubility | Low in water; soluble in DMSO | Used to prepare stock solutions |
| Typical storage | -20 °C, desiccated, protected from light | Common laboratory practice |
| Analytical method | LC-MS/MS | Detects parent compound and metabolites |
| Common test matrix | Urine or blood | Used in anti-doping analysis |
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
== Production == Small amounts of fission products are naturally formed as the result of either spontaneous fission of natural uranium, which occurs at a low rate, or as a result of neutrons from radioactive decay or reactions with cosmic ray particles. The microscopic tracks left by these fission products in some natural minerals (mainly apatite and zircon) are used in fission track dating to provide the cooling (crystallization) ages of natural rocks. The technique has an effective dating range of 0.1 Ma to >1.0 Ga depending on the mineral used and the concentration of uranium in that mineral. About 1.5 billion years ago in a uranium ore body in Africa, a natural nuclear fission reactor operated for a few hundred thousand years and produced approximately 5 tonnes of fission products. These fission products were important in providing proof that the natural reactor had occurred. Fission products are produced in nuclear weapon explosions, with the amount depending on the type of weapon. The largest source of fission products is from nuclear reactors. In current nuclear power reactors, about 3% of the uranium in the fuel is converted into fission products as a by-product of energy generation. Most of these fission products remain in the fuel unless there is fuel element failure or a nuclear accident, or the fuel is reprocessed.
Worldwide, about 80% of people experience some form of lactose intolerance as they age past infancy, but there are significant differences between populations and regions. As few as 5% of northern Europeans are lactose intolerant, while as many as 90% of adults in parts of Asia are lactose intolerant. In northern European countries, early adoption of dairy farming conferred a selective evolutionary advantage to individuals that could tolerate lactose. This led to higher frequencies of lactose tolerance in these countries. For example, almost 100% of Irish people are predicted to be lactose tolerant. Conversely, regions of the south, such as Africa, did not adopt dairy farming as early and tolerance from milk consumption did not occur the same way as in northern Europe. Lactose intolerance is common among people of Jewish descent, as well as from West Africa, the Arab countries, Greece, and Italy. Different populations will present certain gene constructs depending on the evolutionary and cultural pre-settings of the geographical region.
Sir Henry Norris, the then Arsenal chairman, argued that Arsenal be promoted for their "long service to league football", having been the first League club from the South of England. It has been alleged that this was due to backroom deals and even outright bribery by Sir Henry Norris, colluding with his friend John McKenna, the chairman of Liverpool and the Football League, who recommended Arsenal's promotion at the AGM. No conclusive proof of wrongdoing has come to light, though other aspects of Norris's financial dealings unrelated to the promotion controversy have fuelled speculation on the matter. Norris resigned as chairman and left the club in 1929, having been found guilty by the Football Association of financial irregularities; he was found to have misused his expenses account, and to have pocketed the proceeds of the sale of the Arsenal team bus.
Artesunate is a medication used to treat malaria. The intravenous form is preferred to quinine for severe malaria. Often it is used as part of combination therapy, such as artesunate plus mefloquine. It is not used for the prevention of malaria. Artesunate can be given by injection into a vein, injection into a muscle, by mouth, and by rectum. The most common side effects include kidney failure requiring dialysis, hemoglobinuria (the presence of hemoglobin in urine) and jaundice. Artesunate is generally well tolerated. Side effects may include a slow heartbeat, allergic reaction, dizziness, and low white blood cell levels. During pregnancy it appears to be a safer option, even though animal studies have found harm to the baby. Use is likely fine during breastfeeding. It is in the artemisinin class of medication. Artesunate was developed by Liu Xu in 1977. It is on the World Health Organization's List of Essential Medicines. It was approved for medical use in the United States in May 2020. It is in the class of medications known as artemisinins, which are derivatives from "qinghao", or sweet wormwood plant (Artemisia annua).
Sources: en.wikipedia.org
In the United States, it also operates under the Speedway brand (predominantly in the Midwest and on the East Coast) and as Stripes Convenience Stores within the West South Central states. Both Speedway and Stripes operate alongside 7-Eleven's namesake stores in several American markets. 7-Eleven also operates A-Plus locations, licensing the name from its owner, Energy Transfer Partners, a fellow company based in the Dallas–Fort Worth metroplex. However, most of these stores have since been rebranded as standard 7-Eleven stores.
The need for fuel declined in the Soviet Union from the 1970s to the 1980s, both per ruble of gross social product and per ruble of industrial product. The decline was very rapid between 1965 and 1970, then slowed between 1970 and 1975. From 1975 to 1980, the decline continued at an even slower rate, with fuel requirements per ruble of gross social product decreasing by only 2.6%. David Wilson, a historian, believed that the gas industry would account for 40% of Soviet fuel production by the end of the century. His theory did not come to fruition because of the USSR's collapse. According to Wilson, the Soviet Union was, in theory, well-positioned to avoid an energy crisis and could have sustained economic growth rates of 2–2.5% during the 1990s, supported by its energy resources. However, the energy sector faced many difficulties, among them the country's high military expenditure and hostile relations with the First World. In 1991, the Soviet Union had a pipeline network of 82,000 kilometres (51,000 mi) for crude oil and another 206,500 kilometres (128,300 mi) for natural gas. Petroleum and petroleum-based products, natural gas, metals, wood, agricultural products, and a variety of manufactured goods, primarily machinery, arms and military equipment, were exported. In the 1970s and 1980s, the USSR heavily relied on fossil fuel exports to earn hard currency. At its peak in 1988, it was the largest producer and second-largest exporter of crude oil, surpassed only by Saudi Arabia.
== Release history == Reek of Putrefaction was first released in 1988. When released, Reek of Putrefaction reached No. 6 on the UK Indie Chart, establishing Carcass' earlier grindcore sound. The late BBC Radio 1 DJ John Peel declared it his favourite album of 1988, in an interview for British newspaper The Observer. Reek of Putrefaction was re-released in 1994. In 2002, the album was reissued. The album was re-released in 2008 as part of an ongoing series of Carcass reissues to tie in with their reunion. The main album, along with the demo Flesh Ripping Sonic Torment, is presented as one side of a dualdisc, while the DVD side features the first part of an extended documentary titled The Pathologist's Report Part I: Incubation. Later editions contain the album on a CD and the documentary on a separate DVD. The album is presented in a 12-panel digipak with full lyrics and artwork and is sealed in a white medical bag with sticker, to hide the controversial cover art.
== Theory == Atmosphere within the package can be modified passively or actively. In passive MAP, the high concentration of CO2 and low O2 levels in the package is achieved over time as a result of respiration of the product and gas transmission rates of the packaging film. This method is commonly used for fresh respiring fruits and vegetables. Reducing O2 and increasing CO2 slows down respiration rate, conserves stored energy, and therefore extended shelf life. On the other hand, active MA involves the use of active systems such as O2 and CO2 scavengers or emitters, moisture absorbers, ethylene scavengers, ethanol emitters and gas flushing in the packaging film or container to modify the atmosphere within the package. The mixture of gases selected for a MA package depends on the type of product, the packaging materials and the storage temperature. The atmosphere in an MA package consists mainly of adjusted amounts of N2, O2, and CO2. Reduction of O2 promotes delay in deteriorative reactions in foods such as lipid oxidation, browning reactions and growth of spoilage organisms. Low O2 levels of 3-5% are used to slow down respiration rate in fruits and vegetables. In the case of red meat, however, high levels of O2 (~80%) are used to reduce oxidation of myoglobin and maintain an attractive bright red color of the meat. Meat color enhancement is not required for pork, poultry and cooked meats; therefore, a higher concentration of CO2 is used to extend the shelf life. Levels higher than 10% of CO2 are phytotoxic for fruit and vegetables, so CO2 is maintained below this level.
The redeeming feature of his trip was a dish of venison, he thought, served with a confit of pear in mulled wine and Savoy cabbage with a red wine and smoked chocolate sauce, but he otherwise felt that the food was "over-worked" and the service "peculiarly amateurish".
Sources: en.wikipedia.org
Anti-doping and clinical laboratories commonly use liquid chromatography-tandem mass spectrometry. The method can identify GW501516 and its metabolites in urine or blood. Detection depends on sample timing and the amount present.
PPARδ is a nuclear receptor that regulates genes linked to fatty acid oxidation and energy metabolism. Activation can alter lipid handling and energy use in experimental models. The full range of effects in humans is still under study.
The solid compound is generally stable when kept cold, dry, and protected from light. Solutions may degrade faster, so laboratory protocols often specify fresh preparation or cold storage. Stability can depend on solvent, concentration, and container.
Rodent studies reported increased endurance and fat oxidation after GW501516 exposure. Long-term studies also found higher rates of some tumors, which led to halted development.